Advertisement

International Journal of Hematology

, Volume 79, Issue 4, pp 400–404 | Cite as

No Association of the Plasminogen Activator Inhibitor-1 Promoter 4G/5G Polymorphism with Inhibitor Level during Basal Transcription In Vitro

Article
  • 39 Downloads

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) has been shown to be an independent risk factor for coronary artery disease, myocardial infarction, and cerebrovascular events. Previous studies on variations in plasma PAI-1 levels and associations between PAI-1 levels and PAI-1 genotypes have suggested that PAI-1 expression maybe regulated in a genotype-specific manner by insulin, hypertriglyceridemic very low-density lipoprotein, and lipoprotein. We investigated whether basal transcription of the PAI-1 gene also is regulated in a genotype-specific manner. Allele-specific polymerase chain reaction—amplified fragments containing a 4G/5G polymorphism of the PAI-1 gene promoter were ligated into the chloramphenicol acetyltransferase (CAT) reporter gene. The constructs of p4G-CAT or p5G-CAT and pSVβ-galactosidase as an internal control were transiently cotransfected into human HepG2 hepatoma cells. Electrophoresis mobility shift assays (EMSA) employed a fragment from positions -687 to -664 (4G allele) or from -688 to -664 (5G allele) labeled with adenosine triphosphate tagged with phosphorous 32 in the 7 position and used nuclear extracts of HepG2 cells. Analysis of CAT produced by constructs containing the PAI-1 4G or 5G allele showed similar 3-fold increases in CAT activity in the PAI-1 4G/4G and PAI-1 5G/5G constructs, compared with the CAT activity in the pCAT3-Basic construct. Analyses using the probes containing the 4G or 5G allele site in the EMSA assay revealed no difference in the binding of nuclear protein. Our in vitro assay of basal transcription suggests no difference in the transcriptional activities of the alleles of the PAI-1 4G/5G polymorphism.

Key words

PAI-1 Polymorphism Allele-specific polymerase chain reaction EMSA 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chandler WL. A kinetic model of the circulatory regulation of tissue plasminogen activator.Thromb Haemost. 1991;66:321–328.PubMedGoogle Scholar
  2. 2.
    Ray S, Panja M. Current understanding of pathogenesis of coronary artery disease and its future implications.J Indian Med Assoc. 2000;98:710–711,714,718.PubMedGoogle Scholar
  3. 3.
    Nordt TK, Peter K, Ruef J, Kubler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease.Thromb Haemost 1999;82(suppl 1:14–18.PubMedGoogle Scholar
  4. 4.
    Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.Arterioscler Thromb Vasc Biol. 2000;20:2019–2023.CrossRefPubMedGoogle Scholar
  5. 5.
    Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death.Int J Cardiol. 2002;85:277–283.CrossRefPubMedGoogle Scholar
  6. 6.
    Wagner A, Herkner H, Schreiber W, et al. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction.Thromb Haemost. 2002;88:180–185.CrossRefPubMedGoogle Scholar
  7. 7.
    Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach.Pathophysiol Haemost Thromb. 2002;32:308–311.CrossRefPubMedGoogle Scholar
  8. 8.
    Vaya A, Mira Y, Martinez M, et al. Biological risk factors for deep vein thrombosis.Clin Hemorheol Microcirc. 2002;26:41–53.PubMedGoogle Scholar
  9. 9.
    Lip GY, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: the West Birmingham Stroke Project.Blood Coagul Fibrinolysis. 2002;13:339–347.CrossRefPubMedGoogle Scholar
  10. 10.
    Topcuoglu MA, Haydari D, Ozturk S, Ozcebe OI, Saribas O. Plasma levels of coagulation and fibrinolysis markers in acute ischemic stroke patients with lone atrial fibrillation.Neurol Sci. 2000;21:235–240.CrossRefPubMedGoogle Scholar
  11. 11.
    Francis CW Plasminogen activator inhibitor-1 levels and polymorphisms.Arch Pathol Lab Med. 2002;126:1401–1404.PubMedGoogle Scholar
  12. 12.
    Balta G, Altay C, Gurgey A. PAI-1 gene 4G/5G genotype: a risk factor for thrombosis in vessels of internal organs.Am J Hematol. 2002;71:89–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Jeng JR. Association of PAI-1 gene promoter 4G/5G polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension.Am J Hypertens. 2003;16:290–296.CrossRefPubMedGoogle Scholar
  14. 14.
    Juhan-Vague I, Morange PE, Frere C, et al. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study.J Thromb Haemost. 2003;1:2322–2329.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Festa A, D’Agostino R Jr, Rich SS, Jenny NS, Tracy RP, Haffner SM. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.Circulation. 2003;107:2422–2427.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Diurnal variation in PAI-1 activity predominantly confined to the 4G-allele of the PAI-1 gene.Thromb Haemost. 2002;88:794–798.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Nordt TK, Eschenfelder E, Peter K, Sobel BE, Bode C. Independence of growth factor induced plasminogen activator inhibitor type-1 (PAI-1) expression from the 4G/5G polymorphism of the PAI-1 gene.Thromb Haemost. 2003;90:36–42.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Crainich P, Jenny NS, Tang Z, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly.J Thromb Haemost. 2003;1:1799–1804.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Falk G, Almqvist A, Nordenhem A, Svensson H, Wiman B. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene.Fibrinolysis. 1995;9:170–174.CrossRefGoogle Scholar
  20. 20.
    Godambe SA, Chaplin DD, Takova T, Bellone CJ. An upstream NFIL-6-like site located within a DNase I hypersensitivity region mediates LPS-induced transcription of the murine IL-1 beta gene.J Immunol. 1994;153:143–152.PubMedGoogle Scholar
  21. 21.
    Gorman CM, Moffat LF, Howard BH. Recombinant genomes that express chloramphenicol acetyltransferase in mammalian cells.Mol Cell Biol. 1982;2:1044–1051.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Dignam JD, Martin PL, Shastry BS, Roeder RG. Eukaryotic gene transcription with purified components.Methods Enzymol. 1983; 101:582–598.CrossRefPubMedGoogle Scholar
  23. 23.
    Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.J Biol Chem. 1993;268:10739–10745.PubMedGoogle Scholar
  24. 24.
    Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.Proc NatlAcad Sci U S A. 1995;92:1851–1855.CrossRefGoogle Scholar
  25. 25.
    Ferrer-Antunes C. Polymorphisms of coagulation factor genes: a review.Clin Chem Lab Med. 1998;36:897–906.CrossRefPubMedGoogle Scholar
  26. 26.
    Grant PJ, Humphries SE. Genetic determinants of arterial thrombosis.Baillieres Best Pract Res Clin Haematol. 1999;12:505–532.CrossRefPubMedGoogle Scholar
  27. 27.
    Matsubara Y, Murata M, Isshiki I, et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.Int J Hematol. 1999;69:43–47.PubMedGoogle Scholar
  28. 28.
    Yasuda S, Tsutsumi A, Atsumi T, et al. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies.J Rheumatol. 2002;29:1192–1197.PubMedGoogle Scholar
  29. 29.
    Doggen CJ, Bertina RM, Cats VM, Reitsma PH, Rosendaal FR. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction.Thromb Haemost 1999;82:115–120.CrossRefPubMedGoogle Scholar
  30. 30.
    McCormack LJ, Semple JI, Stickland MH, Barrett JH, Grant PJ. The effect of number of days in culture and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells.Thromb Res. 1998; 92:199–206.CrossRefPubMedGoogle Scholar
  31. 31.
    Panahloo A, Mohamed-Ali V, Gray RP, Humphries SE, Yudkin JS. Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene.Atherosclerosis. 2003;168:297–304.CrossRefPubMedGoogle Scholar
  32. 32.
    Chen YQ, Sloan-Lancaster J, Berg DT, Richardson MA, Grinnell B, Tseng-Crank J. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells.Thromb Haemost. 2001;86:1563–1572.CrossRefPubMedGoogle Scholar
  33. 33.
    Byrne CD, Wareham NJ, Martensz ND, Humphries SE, Metcalfe JC, Grainger DJ. Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels.Atherosclerosis. 1998;140:45–53.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  1. 1.State Key Laboratory of Experimental Hematology, Institute of HematologyChinese Academy of Medical SciencesTianjinChina

Personalised recommendations